Superiority claims require a study designed to establish superiority

AI-verifiedblockerFDA guidance · non-bindingRaised as a question — a person decides

Rule

A claim of superior effectiveness over a named comparator is misleading if it is based on a study that was not designed to test superiority of the product against that comparator, even if both products showed statistically significant benefit versus placebo.

Check

For any head-to-head or comparative superiority claim, confirm the underlying study's design and stated objectives included testing superiority of the product against that specific comparator, not merely parallel comparison to placebo. A violation looks like a superiority claim drawn from a study where the comparator arm was included only for assay sensitivity.

Escalate when

Always — requires review of the study's pre-specified objectives and design to confirm it was built to support the comparative claim.

Where this comes from

Q.10/A.10, Example 2 · page 21. The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

…— both Drug A and Drug B are approved for the same indication and patient population and have similar risk profiles. Furthermore, the directions in the FDA-required labeling enable Drug A to be safely and effectively used under the conditions presented in the promotional material. This promotional communication could be considered consistent with the FDA-required labeling. Is this truthful and non-misleading? No. The promotional material is misleading because it makes a claim of superior effectiveness for Drug A versus Drug B based on a study that was not designed to establish superiority of Drug A to Drug B. Thus, the CFL promotional communication would not be consistent with the recommendations in Q.6/A.6 and Q.8/A.8. If the firm wishes to present data and information from this study, it should do so in a truthful and non-misleading way. For example, the firm could describe the study design and objectives, including the material limitations of both, and include prominent contextual information that the study was not d…

Open the original at page 21 on fda.gov ↗Read our full copy →

Document: FDA guidance: Medical Product Communications that Are Consistent With the FDA-Required Labeling – Questions and Answers (final)
Version: as retrieved — the publisher does not version this document; the fingerprint below identifies the exact file
Retrieved: 2026-09-21 from www.fda.gov
Fingerprint: 1a18b7f242bfbbf897f198df…

FDA guidance describes the agency's current thinking. It is not binding law, and this rule is a recommendation, not an obligation.

Applies when

Naturepromotional

Basisconsistent-with-labeling

How this rule was checked

Citation proven by script and passed an independent verifier running on a different model. Not yet confirmed by a human.

Drafted
claude-code:sonnet · 2026-09-21
Independent verification — revise
claude-code:opus · 2026-09-21
Reviewer's reasons
- The source does establish the core proposition: in Q.10/A.10 Example 2 FDA states the promotional material 'is misleading because it makes a claim of superior effectiveness for Drug A versus Drug B based on a study that was not designed to establish superiority of Drug A to Drug B,' and the closing paragraph generalizes it ('The CFL promotional communication should not contain representations or suggestions that are not supported by appropriate evidence, such as any representation or suggestion of Drug A's superior effectiveness over Drug B.'). This is FDA's own analytic conclusion about the facts, not a stray quote from an illustrative narrative, so the generalization to comparative superiority claims is fair.
- The rule body is internally inconsistent with its own title and is too lenient as written. The title says a superiority claim requires 'a study designed to establish superiority,' but the body accepts a study 'designed to test superiority (or non-inferiority) against that comparator,' and the Check repeats 'superiority/non-inferiority.' A study designed and powered only for non-inferiority does not establish superiority; the source mentions non-inferiority only because the example study was designed for neither, and it says the data 'should not be interpreted as providing evidence of either superiority or non-inferiority.' As drafted, a reviewer would clear a superiority claim resting on a non-inferiority trial.
- 'Judgment' is right: this turns on reading the study's pre-specified design and objectives against the claim, not on presence/absence of a string. 'Guidance' is right: the source is a nonbinding FDA guidance. 'Blocker' is defensible for an unsupported comparative efficacy claim, and the locator (Q.10/A.10, Example 2) matches the quoted sentence.
- applies_when (promotional + basis consistent-with-labeling) matches the source's stated scope: the Q.6/A.6 and Q.8/A.8 recommendations are 'applicable only to drug and device labeling and prescription drug and restricted device advertising that are consistent with the FDA-required labeling.'
Revised by the drafter
claude-code:sonnet · 2026-09-21
Independent verification — pass
claude-code:opus · 2026-09-21
Reviewer's reasons
- The quote is a complete sentence from Q.10/A.10 Example 2 and is FDA's own conclusion about the communication ('The promotional material is misleading because it makes a claim of superior effectiveness for Drug A versus Drug B based on a study that was not designed to establish superiority of Drug A to Drug B.'), not a narrative detail of the scenario, so the generalization to comparative superiority claims tracks the stated reasoning rather than the facts of the example.
- The same answer closes with the general statement that the communication 'should not contain representations or suggestions that are not supported by appropriate evidence, such as any representation or suggestion of Drug A's superior effectiveness over Drug B,' and Q.6/A.6 independently says firms' communications 'should not overstate the findings of or the conclusions that can be drawn from such studies or analyses' — so the rule is not resting on the example alone.
- Not overstated: FDA itself characterizes the claim as 'misleading,' and the rule says 'is misleading' in the same conditional terms; the added clause about both products beating placebo is taken from the example's own facts and narrows rather than broadens the rule.
- Atomic: a single checkable requirement — a superiority claim must rest on a study designed to test superiority against that comparator.
- Determinism 'judgment' is right: deciding whether a study's design and pre-specified objectives support a comparative claim is not a presence/absence or literal-match test.
- Authority 'guidance' matches the source document; the rule does not claim to be a regulation. Severity 'blocker' is defensible because FDA labels this presentation misleading, which carries FD&C Act consequences. applies_when (promotional, consistent-with-labeling) matches the guidance's stated limit of its recommendations to CFL promotional communications, and the locator points to the right example.